Trials / Not Yet Recruiting
Not Yet RecruitingNCT07515820
SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Meng Qiu · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of SHR-3821 combined with fruquintinib in the advanced colorectal cancer after failure of standard therapy
Detailed description
This is a single-center, open-label, exploratory phase II clinical trial designed to investigate the efficacy and safety of SHR-3821 in combination with fruquintinib for the treatment of metastatic colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-3821 and fruquintinib | SHR-3821, administered by intravenous infusion Fruquintinib, administered orally |
Timeline
- Start date
- 2026-04-27
- Primary completion
- 2027-07-28
- Completion
- 2028-04-28
- First posted
- 2026-04-07
- Last updated
- 2026-04-07
Source: ClinicalTrials.gov record NCT07515820. Inclusion in this directory is not an endorsement.